Guangzhou Pharmaceutical Holdings Limited (GPHL) aims to allocate RMB1.27 billion (MOP1.43 billion/US$175 million) for investments in Hengqin and between RMB10 billion (MOP11.3 billion/US$1.38 billion) and RMB15 billion (MOP16.9 billion/US$2.07 billion) for research and development throughout the 15th Five-Year Plan span (2026–2030), as it accelerates a global growth strategy centered in Macau.
According to a report by Macao Daily News, the announcement of the plan took place during the "2026 Spring Reception and Sixth Anniversary Celebration" of Guangzhou Pharmaceutical Group (Macau) International Development Industry Co., Ltd. The firm also detailed its strategic direction in traditional Chinese medicine (TCM) and global market expansion.
GPHL chairman Li Xiaojun stated that the investment in Hengqin will support the development of an advanced pharmaceutical manufacturing center aimed at combining research, production, and industry transformation.
The initiative aims to promote synchronized growth in the Guangdong-Hong Kong-Macau Greater Bay Area while acting as a foundation for expansion into Southeast Asia, Portuguese-speaking nations, and the Middle East.
Also Read: ADNOC, OMV Advance Plans for Forming Borouge Group With New Deal
"The collective will utilize Macau as a strategic focal point and enhance regional cooperation," Li stated, noting that the Hengqin initiative seeks to create a new growth driver for the pharmaceutical industry with both local and global influence.
In the 15th Five-Year Plan period, GPHL plans to allocate between RMB10 billion and RMB15 billion for research and development. The team plans to work with over ten top universities to create joint research centers, emphasizing a market-driven platform that connects industry, education, research, and application.
Also Read: Report Urges to Advance Sustainable Agriculture in Viet Nam
The company stated that its overall strategy will be guided by four main areas: modernization, technology, digitalization, and internationalization. In Macau, GPHL collaborates with research teams from the University of Macau (UM) and the Macau University of Science and Technology (MUST) to enhance the secondary development of existing TCM products and boost scientific expertise.
The group intends to merge industrial assets with digital technologies and artificial intelligence (AI) to enhance efficiency and foster innovation throughout the Chinese medicine value chain.
Regarding internationalization, GPHL International will collaborate with its research and development as well as treasury centers in Hong Kong to venture into foreign markets.
Also Read: POSCO International to Establish Rare Earth Supply Chain
The company will focus on Southeast Asia, Portuguese-speaking nations, and the Middle East, forming specialized teams in Vietnam, Malaysia, Indonesia, Australia, and Ghana. It also aims to expedite the registration of a preliminary group of nine Chinese medicine products in Vietnam to aid the localization of its global business.